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Abstract
Background: Resistance to chemotherapy is common in gastroesophageal cancer. Mechanisms of resistance are
incompletely characterised and there are no predictive biomarkers in clinical practice for cytotoxic drugs. We used
new cell line models to characterise novel chemotherapy resistance mechanisms and validated them in tumour
specimens to identify new targets and biomarkers for gastroesophageal cancer.
Methods: Cell lines were selected for resistance to oxaliplatin, cisplatin and docetaxel and gene expression
examined using Affymetrix Exon 1.0 ST arrays. Leads were validated by qRT-PCR and HPLC of tumour metabolites.
Protein expression and pharmacological inhibition of lead target SPHK1 was evaluated in independent cell lines,
and by immunohistochemistry in gastroesophageal cancer patients.
Results: Genes with differential expression in drug resistant cell lines compared to the parental cell line they
were derived from, were identified for each drug resistant cell line. Biological pathway analysis of these gene
lists, identified over-represented pathways, and only 3 pathways - lysosome, sphingolipid metabolism and p53
signalling- were identified as over-represented in these lists for all three cytotoxic drugs investigated. The majority
of genes differentially expressed in chemoresistant cell lines from these pathways, were involved in metabolism of
glycosphingolipids and sphingolipids in lysosomal compartments suggesting that sphingolipids might be important
mediators of cytotoxic drug resistance in gastroeosphageal cancers . On further investigation, we found that drug
resistance (IC50) was correlated with increased sphingosine kinase 1(SPHK1) mRNA and also with decreased
sphingosine-1-phosphate lysase 1(SGPL1) mRNA. SPHK1 and SGPL1 gene expression were inversely correlated.
SPHK1:SGPL1 ratio correlated with increased cellular sphingosine-1-phosphate (S1P), and S1P correlated with drug
resistance (IC50). High SPHK1 protein correlated with resistance to cisplatin (IC50) in an independent gastric cancer
cell line panel and with survival of patients treated with chemotherapy prior to surgery but not in patients treated
with surgery alone. Safingol a SPHK1 inhibitor, was cytotoxic as a single agent and acted synergistically with
cisplatin in gastric cancer cell lines.
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Conclusion: Agents that inhibit SPHK1 or S1P could overcome cytotoxic drug resistance in gastroesophageal
cancer. There are several agents in early phase human trials including Safingol that could be combined with
chemotherapy or used in patients progressing after chemotherapy.
Keywords: Gastroesophageal cancer, Chemoresistance, Sphingosine-1-phosphate, Sphingosine kinase 1,
Sphingosine-1-phopshate lyase
Background
The clinical outcomes for gastroesophageal cancer are
poor. One year survival is only 40–50 % and 5 year sur-
vival 10–20 % [1]. At the time of clinical diagnosis only
30–40 % patients have loco-regionally confined disease
that is amenable to potentially curative therapy and the
majority of patients relapse systemically after such treat-
ment [1].
These outcomes are largely the consequence of sys-
temic dissemination at a very early stage and indicate
the importance of systemic therapies in disease manage-
ment [2, 3]. Accordingly, cytotoxic chemotherapy has
value as neo-adjuvant, adjuvant and palliative treatment
[2–4]. Cisplatin, oxaliplatin and docetaxel are amongst
the most active cytotoxics and key components of com-
bination chemotherapy regimens [2, 5]. Nevertheless, re-
sistance to cytotoxic drugs is common and severely
limits the effectiveness of these treatments by resulting
in the delivery of ineffective and toxic therapy.
Accordingly, identification of predictive biomarkers for
chemotherapy in gastroesophageal cancer are urgently
needed in clinical practice and would enable a stratified
approach to treatment selection, and optimise clinical
and cost effectiveness. Despite extensive investigation
there are no predictive biomarkers for chemotherapy
that are recommended for clinical use in gastroesopha-
geal cancer. More recently the use of global molecular
analysis tools such as gene expression profiling, array-
CGH, exome and whole genome sequencing, has pro-
vided more promising leads for predictive biomarkers
for chemotherapy in gastroesophageal cancer [6, 7].
Predictive biomarkers for chemotherapy resistance may
also have value as therapeutic targets for agents that
would combine effectively with cytotoxic drugs. A clinical
proof of principle for the safety, tolerability and effective-
ness of combining targeted agents with chemotherapy as
part of a biomarker directed stratified therapy approach,
has been demonstrated recently in gastroesophageal
adenocarcinoma, combining trastuzumab with cisplatin
and 5FU in patients whose tumours are HER 2 positive
[8]. However only 10–15 % of gastroesophageal adenocar-
cinomas are HER2 positive and the identification of clinic-
ally effective targeted agents has proven challenging in
gastroesophageal cancer, with Phase III trials evaluating
the addition of targeted therapies against Epidermal
Growth Factor Receptor (EGFR), Vascular Endothelial
Growth Factor (VEGF), Mammalian Target of Rapamycin
(mTOR) Mamalian mTOR, to cytotoxic chemotherapy,
not demonstrating any benefit [9–12], and there are no
targeted therapy options at all for squamous cell carcin-
oma of the esophagus. More recently, the addition of the
VEGFR-2 targeting agent Ramicurumab to paclitaxel
chemotherapy has been shown to be beneficial in a phase
III randomised controlled trial, but as yet there are no
predictive biomarkers for Ramicurimab, which is likely to
significantly limit the cost effectiveness of this treatment
[13]. Overall, there is a clear ongoing clinical need to iden-
tify further new targets and biomarker combinations for
gastroesophageal cancer, in particular those which might
combine effectively with cytotoxic chemotherapy.
In order to address this we utilised gastroeosphageal
cancer cell lines selected for resistance to cisplatin, oxali-
platin and docetaxel as models for the identification of
new markers of drug resistance and candidate novel
therapeutic targets. Such models have been widely used
and have provided new insights into mechanisms of
drug action and resistance, but translation from such
studies to clinically useful targets or biomarkers has
been more limited [14]. In light of this, and the more re-
cent demonstration of the usefulness of global molecular
profiling tools with gastroesophageal cancer cell line
models to identify predictive markers and targets [6, 7],
we used global gene expression profiling on our cyto-
toxic resistant cell lines to identify lead molecules for
further investigation. To further determine their clinical
utility as predictive biomarkers and/or novel therapeutic
targets leads were validated by quantitative real-time
polymerase chain reaction (qRT-PCR), assay of relevant
tumour metabolites in key biological pathways, pharmaco-
logical inhibition of an identified target, and evaluation of
predictive and prognostic value in an independent panel
of gastric cancer cell lines and tumour tissues from gastro-
esophageal cancer patients.
Methods
Cell Lines and cell culture
Human esophageal squamous carcinoma (OE21), adeno-
carcinoma of oesophagus (OE33), and adenocarcinoma of
gastric cardia (AGS) cancer cell lines were obtained from
the European Collection of Animal Cell Culture (Centre
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for Applied Microbiology and Research, Salisbury, UK).
OE21, OE33 and AGS cell lines were cultured and main-
tained in RPMI - 1640 medium, supplemented with 10 %
(v/v) foetal calf serum and 1 % (v/v) penicillin/strepto-
mycin (100 000 U/l penicillin, 100 mg/l streptomycin).
Gastric cancer cell lines Kato III, NCI-N87 and Hs746T
were obtained from American Type Culture Collection,
Manassas, VA, USA), and cultured as recommended by
the supplier. Gastric cancer cell lines AZ521, Fu97, IM95,
Ist1, MKN1, MKN45, MKN7,MKN28, MKN45 and
TMK1 cells were obtained from the Japanese Collection
of Research Bioresources and cultured as recommended .
The SCH gastric cancer cells were a gift from Yoshiaki Ito
(Institute of Molecular and Cell Biology, Singapore) and
grown in RPMI supplemented with 10 % (v/v) foetal calf
serum and 1 % (v/v) penicillin/streptomycin (100 000 U/l
penicillin, 100 mg/l streptomycin). The gastric cancer cell
lines YCC1, YCC3, YCC6, YCC7, YCC10, YCC11and
YCC16 cells were a gift from Sun-Young Rha (Yonsei
CancerCenter, Seoul, South Korea) and were grown in
minimum essential medium supplemented with 10 % fetal
bovine serum, 100Uml1penicillin, 100Uml1 streptomycin
and 2 mmol l1L-glutamine (Invitrogen, Carlsbad, CA,
USA). All cells were cultured at 37 °C in a humidified at-
mosphere containing 5 % carbon dioxide. All cell lines
were tested and authenticated by the cell line bank pro-
vider (ECACC, ATCC, JCRB) or the originating institution
(YCC and SCH) by several methods including Short Tan-
dem Repeat profiling and/or cytogenetics(and cells utilised
within 6 months of receipt). Prior to this study, we re-
authenticated the cell lines by comparing their genome-
wide gene expression profiles (Affymetrix Exon 1.0 ST Ar-
rays (1 084 639 exons and over 300 000 transcript clusters
on each oligonucleotide microarray; www.affymetrix.com)
and/or mutational profiles, and/or their genome-wide
copy number (Agilent Human Genome244A CGH Micro-
arrays, Agilent Technologies, Santa Clara, CA) to that in
public databases and published literature. Ethical approval
was not required for the use of the cell lines in this
investigation.
Drugs and reagents
Oxaliplatin, cisplatin, docetaxel and 3-((4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide,MTT) solutions
were obtained from Sigma-Aldrich(UK). RPMI-1640-
(GlutaMAX) culture medium from GIBCO(BRL); Foetal
bovine serum from Thermo Scientific; Penicillin/
streptomycin were obtained from Sigma-Aldrich (UK).
All reagents were molecular biology grade unless other-
wise stated.
Cell Viability Assays
MTT and MTS assay were used as indicated to assess
cytotoxicity. Assays were performed on 96- well plates
with complete media alone (no cells) as a background
control, and blank and vehicle controls included on each
plate. Unless otherwise stated, all measurements were
performed in triplicate independent experiments with
triplicate data points within an assay. Paired parental
and resistant daughter lines were tested in parallel on
the same plate. The MTT assay was performed as previ-
ously described [15] with absorbance measured at 570
and 690 nm using Gen 5 v.2 software on a multi-well
plate reade (BioTek, Synergy HT). MTS assays were
performed using a commercially available kit(MTS kit;
Promega, Madison, WI, USA), according to the manu-
facturer’s instructions. In all cases cell lines were seeded
in 100 μl of media in a 96-well plate and left to adhere
for 24 h, 100 μl of drug diluted in media was added and
incubated for 72 h at 37 °C and 5 % CO2 and absorb-
ance measured using an EnVision2104 multi-label plate
reader (Perkin Elmer, Turku, Finland) at 490 nm. A dose
curve was fitted and IC50 values representing the drug
concentration required to elicit a 50 % growth inhibition
compared to vehicle control were calculated in Prismv6
software (GraphPad PRISM v.5.02, La Jolla, CA, USA).
Generation of resistant cell lines
OE21, OE33 and AGS cell lines were selected for pro-
gressive resistance to oxaliplatin, cisplatin and docetaxe
las described previously [15]. Briefly, selection began at a
drug dose that was 20 fold less than the half maximal in-
hibitory concentration (IC50) concentration. Cells were
grown at the same drug concentration over 4 passages
and then cell viability tests performed. Drug concentra-
tions were increased 2 to 4 - fold until the IC50 daugh-
ter/IC50 parental ≥ 3. The panel of drug resistant cell
lines generated in this way were AGSCIS5, AGSOX8,
AGSDOC6, OE33CIS4, OE33OX4 and OE21OX4 with the
subscript denoting the drug and final concentration of
drug (μM) that cells were exposed to. Changes in IC50
during generation of drug resistant cell lines are pre-
sented in Additional file 1: Additional information 1.
Gene expression Profiling
Gene expression was assessed using the Affymetrix Exon
1.0 ST Arrays (1 084 639 exons and over 300 000 tran-
script clusters on each oligonucleotide microarray;
www.affymetrix.com). Details of RNA extraction, sample
preparation and quality control are described in
Additional file 1: Additional Information 2. Gene expres-
sion profiling data is available in MIAME compliant
format in Array Express (www.ebi.ac.uk/arrayexpress)
accession number E-MTAB-2860.
Analysis of gene expression data
Gene expression data was analysed using GeneSpring
v.11.1 (Agilent, Wokingham, UK) and DAVID v6.7 for
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pathway analysis (NIH, Bethesda, MD, USA) [16]. Core
probe sets on the Human Exon 1.0 ST array were proc-
essed using the RMA16 algorithm (Affymetrix, Santa
Clara, CA, USA) that employs quantile normalisation of
log2 transformed data. Data were transformed to the
median of all samples. Further details of gene expression
analysis and details for pathway analysis are described in
Results and Additional file 1: Additional information 3.
Quantitative real-time PCR
Roche LightCycler 480 master mix (Roche Diagnostics
GmbH, Mannheim, Germany) was used, with condi-
tions: 95 °C for 5 min followed by 45 cycles of 95 °C for
10 s and 60 °C for 15 s. The amplified fluorescent signal
was detected and relative quantification was assessed
with LightCycler 480 SW v 1.5(Roche Diagnostics). Gene
expression was normalised to GAPDH and changes in
expression measured relative to the parental line as a
control. PCR primer sequences used (Sigma - Genosys,
Haverhill, UK) are in Additional file 1: Additional
Information 4. For each gene, all experiments were re-
peated in triplicate using RNA extracted from three in-
dependent samples.
Analysis of Spingosine-1-Phosphate
Analysis and quantification of sphingosine-1-phosphate
from cell lines, including the use and preparation of all in-
ternal standards and reagents was using the high perform-
ance liquid chromatography-tandem mass spectrometry
(HPLC-MS/MS) method as described by Bielawski et al.
[17]. Further details of equipment used and preparation of
cell pellets and lipid extraction are provided in Additional
file 1: Additional information 5. Analysis was performed
in duplicate and to limit inter-assay variability each WT
line was analysed in parallel with each drug resistant
daughter line. The level of S1P was determined in pmol/
sample, with samples normalized to total phosphorus
content.
Patients
Formalin fixed paraffin embedded (FFPE) tumour tissues
were obtained from patients with esophageal or gastric
cancers who underwent surgical resection at Aberdeen
Royal infirmary between 2004 and 2009. 36/67 patients
received neo-adjuvant chemotherapy with 3 cycles of
Epirubicin, Cisplatin and Capecitabine prior to surgery.
Clinico-pathological features of patients are detailed in
Table 1 and further details of treatment are provided in
Additional file 1: Additional Information 6. The use of
these tissues was approved by the North of Scotland re-
search ethics committee and proceeded with informed
consent.
Immunohistochemistry
Representative 4 μm sections of FFPE tumours or cell
line pellets were mounted onto glass slides rehydrated
following a standard protocol. Individual cell line pellets
were prepared from cultured cell lines harvested and
fixed in 4 % paraformaldehyde, and further processed for
paraffin embedding as described in [18] Antigen retrieval
was performed by microwaving in 10 mM citrate (pH 6.0)
for 20 min. SPHK1 (1:60, tumours, 1:400 cell lines) rabbit
polyclonal antibody (Abgent, CA, USA) was used with an
autostainer (Dakocytomation, Glostrup, Denmark) and
Table 1 Clinical details of patients treated with surgical resection of gastroesophageal cancers
Variable Score Neo-adjuvant
Chemotherapy
No Neo-adjuvant
Chemotherapy
P value*
Age >Median 9 15 0.073
< Median 27 16
Histology Adenocarcinoma 31 24 0.180
Squamous 5 7
Stage I 11 3 0.109
II 10 12
III 15 16
Site Oesophagus 30 25 0.755
(includes Siewert Type I and II junctional)
6 6
Gastric
(includes Siewert Type III junctional)
Circumferential
Resection Margins
Positive 6 11 0.378
Negative 30 20
There was no significant difference in clinic-pathological characteristics between patients who did and did not receive neo-adjuvant chemotherapy prior to
surgery. SPHK1 immunohistochemistry was performed on this cohort as described. *χ2 test. Two-sided p value
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the CSAII detection system according to the manufactur-
er's instructions. All sections were double scored by two
independent investigators who were blinded to the clinical
data. Overall, more than 90 % agreement in scoring was
observed. Scoring discrepancies were resolved by examin-
ation of sections at a double-headed microscope.
Statistical analysis
All other statistical analyses including survival analysis
were performed using PASW statistics v20 (IBM Cor-
poration, Armonk, NY, USA). Kaplan–Meier survival
curves with log rank test and cox proportional hazards
analysis were used for survival analysis and survival time
was calculated from date of histological diagnosis until
date of death. Fisher’s exact test or Pearson chi-square
was used for the assessment of categorical variables and
Student’s t-test, one way- ANOVA, 2-way ANOVA with
Sidlak post-hoc test for continuous variables. All re-
ported P-values are two sided and p < 0.05 was considered
statistically significant. Combination Index to quantify
synergy between cisplatin and safingol was calculated
using Compusyn(Combosyn, Paramus, NJ).
Results
Lysosomal and sphingolipid metabolism genes are
differentially expressed in drug resistant cancer cell lines
Gene expression was performed using RNA isolated
from AGS, AGSCIS5, AGSOX8, AGSDOC6, OE33,
OE33CIS4, OE33OX4, OE21, OE21OX4 (Fig. 1a), with 3
independent replicates per cell line from three different
passages. Core gene sets were analysed and using thresh-
old of expression ≥ 20th percentile there were 16939 out
of 17881 genes expressed in at least 1 cell line. Principle
component analysis using these 16939 genes revealed
clustering according to cell line rather than drug resist-
ance or histological subtype (Fig. 1b). Statistical filtering
(Unpaired t-test with Benjamini and Hochberg MTC cor-
rected p < 0.05) of these 16939 genes was performed on
each pair of drug resistant versus parental cell line. This
analysis identified differentially expressed genes for drug
resistant gastric adenocarcinoma [AGSCIS5 (n = 1298),
Fig. 1 Development and characterisation by gene expression profiling of cytotoxic drug resistant gastroesophageal cancer cell lines. a Drug resistant
cell lines used in this study (see also Additional file 1). b Principle component analysis of drug resistant cell lines using 16939 genes expressed in at
least 1 cell line (threshold of expression≥ 20th percentile) with 3 independent replicates per cell line from three different passages using Affymetrix
Exon 1.0ST microarrays (see also Additional File 1: Additional information 2). c Only 3 pathways, namely the lysosome, sphingolipid metabolism and
p53 signalling were identified as over-represented in gene set enrichment analysis of genes significantly differentially expressed for all 3 cytotoxic drugs
compared to sensitive parental lines and in each case they were also identified in at least 2 cell lineages (DAVID v6.7 for biological pathway
mapping and gene set enrichment analysis (EASE score, modified Fisher exact p < 0.05 [16]), Paired t-test with Benjamini and Hochberg correc-
tion for multiple testing (corrected P <0.05) to derive the differentially expressed gene set, green = over represented red = not over-
represented. See also Additional file 1: Additional information 7
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AGSOX8 (n = 466), AGSDOC6 (n = 2251)], esophageal
adenocarcinoma [OE33OX4 (n = 2107), OE33CIS4 (n =
2613)] and esophageal squamous cell carcinoma
[OE21OX4 (n = 859)] cell lines compared to the sensitive
parental line.
Gene enrichment analysis (DAVID v6.7, p < 0.05)
identified pathways that were over-represented among
each of these gene lists (Additional file 1: Additional
information 7). A number of pathways reported as be-
ing important in cisplatin,oxaliplatin and docetaxel
drug resistance for example p53 signalling, base exci-
sion repair and DNA replication were identified. Only 3
common ontologies (biological pathways/cell compo-
nent), namely the lysosome, sphingolipid metabolism
and p53 signalling, were identified for all 3 cytotoxic
drugs. For each drug, at least 2 of the gastroesophageal
cancer cell lineages had significant enrichment of these
biological networks in the drug resistance gene set
(Fig. 1c). Accordingly, these pathways were selected for
further investigation as potential novel mechanisms of
cytotoxic drug resistance in gastroesophageal cancer.
The lysosome was identified in the analysis for all 3 cell
lineages and all 3 cytotoxic drugs. A comprehensive
analysis of the published literature and databases re-
vealed that the protein products of the majority of the
genes identified as differentially expressed in the resist-
ant lines in the pathways from the gene enrichment
analysis, were involved in metabolism of glycosphingo-
lipids and sphingolipids in lysosomal compartments.
This was reflected in identification of sphingolipid me-
tabolism in gene set enrichment analysis. These data
suggested that sphingolipids might be important media-
tors of cytotoxic drug resistance in gastroeosphageal
cancers. In support of this hypothesis, our gene expres-
sion profiling data identified increased expression of
sphingosine- kinase 1 (SPHK1), required for metabol-
ism of sphingosine to sphingosine-1-phosphate (S1P),
in all resistant lines and decreased expression of sphingo-
sine -1 Phosphate lysase (SGPL1), catalysing irreversible
lysis of S1P, in 4 out of 6 of the resistant cell lines (AGS-
CIS5, AGSDOC6, OE33OX4, OE33CIS4) compared to their
parental wild type lines (Fig. 2a). Furthermore, there was a
significant inverse correlation observed between SPHK1
mRNA expression and SGPL1 mRNA expression in all
the gastroesophageal cancer the cell lines (R = -0.740,
p = 0.022, Fig. 2b).
Fig. 2 SPHK1 and SGPL1 expression in cytotoxic drug resistant gastroesophageal cancer cell lines. a All drug resistant cell lines showed increased
SPHK1 mRNA expression relative to parental wild type line, and 4 out of 6 also showed decreased SGPL1 mRNA. Data shown is mean (+/- SEM)
from 3 independent replicates per cell line from three different passages using Affymetrix Exon 1.0ST microarrays and validated by qRT-PCR
(see Additional file 1: Additional information 2 and 3). *** p < 0.01 ** p < 0.05 (Student’s t-test). b Inverse correlation between SPHK1 and
SGPL1 mRNA levels (R = -0.740, p = 0.022). Data shown is mean for all drug resistant cell lines and parental wild type lines, 3 independent
replicates per cell line from three different passages measured by qRT-PCR (see also Additional file 1: Additional information 5). c Hypothesis of
increased SPHK1 and decreased SGPL1 leading to increased S1P in gastro-oeosphageal cancer, promoting cell survival and hence cytotoxic
drug resistance
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SPHK1 and SGPL1 mRNA levels measured on microar-
rays were validated by qRT-PCR, with strong correlations
between gene expression measured with each assay
(SPHK1 R = 0.731, p = 0.005, SGPL1 R = 0.867, p = 0.002).
Many previous investigations have identified SPHK1 as
overexpressed in several cancer types including gastric
adenocarcinoma and associated with increased stage and
poor survival [19–21]. In addition, preclinical investiga-
tions in cancer and non-cancer cells demonstrate that
increased SPHK1 is associated with increased produc-
tion of sphingosine-1-phosphate (S1P) in cancer cells
and S1P promotes cell proliferation and angiogenesis,
and inhibits cell death [22–29]. SPHK1 activity and
levels of S1-P have been demonstrated to be involved in
resistance to cytotoxic and targeted agents in a variety of
cancer types, although not in esophageal or gastric can-
cer drug resistance [30–36]. SGPL1 is responsible for
the irreversible cleavage of S1P into hexadecenal and
ethanolamine phosphate, but there has been little inves-
tigation of SGPL1 in human cancers. Recently, in pros-
tate cancer, an inverse relationship between expression
of SPHK1 and SGPL1 was noted and down regulation of
SGPL1 increased production of S1P and was associated
with resistance to docetaxel [37].
Therefore it seemed biologically plausible to hypothe-
sise, based upon the analysis of our gene expression
data, that in gastroesophageal cancer increased expres-
sion of SPHK1, often associated with decreased expres-
sion of SGPL1, would lead to increased S1P potentially a
pathogenic mechanism in gastroesophageal cancer cells,
which would also lead to cytotoxic drug resistance
(Fig. 2c).
Ratio of SPHK1:SGPL1 mRNA correlates with cellular S-1-P
in gastroesophageal cancer cell lines
In order to test this hypothesis we examined the rela-
tionship between the cellular levels of S1P and the ra-
tio of SPHK1 and SGPL1 mRNA expression and drug
resistance in the 4 drug resistant cell lines that demon-
strated increased SPHK1 together with decreased SGPL1 -
AGSCIS5, AGSDOC6,OE33OX4, OE33CIS4. There was a
strong correlation between the SPHK1:SGPL1 mRNA ra-
tio in the drug resistant cell lines and the increase in S1P
observed in the drug resistant cell lines compared to the
relevant parental wild type line (R = 0.981, p = 0.020,
Fig. 3a).
Cellular S-1-P correlates with IC50 in gastroesophageal
cell lines
We further investigated the relationship between drug
resistance and cellular levels of the sphingosine metabol-
ite, S1P. Increased cellular S1P levels correlated with in-
creased IC50 in drug resistant lines (R = 0.690, p = 0.040,
Fig. 3b). This relationship between cellular S1P and IC50
was observed across oxaliplatin, cisplatin and docetaxel
resistant cell lines.
Fig. 3 Relationship between SPHK1 and SGPL1 expression and S1P and cisplatin resistance in gastroesophageal cancer cell lines. a In drug
resistant cell lines that demonstrate increased SPHK1 together with decreased SGPL1 (AGSCIS5, AGSDOC6,OE33OX4, OE33CIS4), the fold change in the
ratio of SPHK1:SGPL1 mRNA correlates with observed increase in cellular S1P in drug resistant cell lines relative to the respective parental cell lines
(R = 0.981, p = 0.020). Data shown is mean for 3 independent replicates per cell line from three different passages measured by qRT-PCR (see also
Additional file 1: Additional information 5). b In the drug resistant cell lines (Fig. 1a), cellular S1P correlates with IC50 to cisplatin, oxaliplatin and
docetaxel, respectively (R = 0.690, p = 0.040). IC50 data determined by MTT assay with each data point in each cell line measured in triplicate with
3 independent replicate experiments. S1P measured using high performance liquid chromatography-tandem mass spectrometry as described in
the text, mean value from duplicate assays
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SPHK1 mRNA correlates with SPHK1 protein expression in
gastroesophageal cell lines
Formalin fixed paraffin embedded individual cell line
pellets were prepared from cultured cells and SPHK1
protein expression was measured by immunohstochem-
istry (IHC) using a pre-determined semi-quantitative
Quick-score. SPHK1 IHC Quick-score = intensity x pro-
portion: intensity scored as 0 = negative, 1 = weak, 2 =
moderate and 3 = strong SPHK1 staining in tumour
cells; positive proportion scored as 0 = 0 %, 1 = 1-10 %,
2 = 11-50 %, 3 = 51-70 %, and 4 = > 70 % tumour cells
positive for SPHK1 staining. In the parental and drug
resistant cell lines a strong correlation between SPHK1
mRNA expression and SPHK1 protein expression was
observed (R = 0.070 p = 0.022 Fig. 4a).
SPHK1 protein expression in an independent panel of
gastric cancer cell lines correlates with resistance to
cisplatin
We examined the relationship between SPHK1 protein
expression measured by IHC, and cisplatin resistance
in an independent panel of 21 gastric cancer cell lines.
The independent panel of 22 gastric cancer cell lines
comprised: Kato III, NCI-N87, Hs746T,AZ521, Fu97,
IM95, Ist1, MKN1, MKN45, MKN74,MKN28,
MKN45,TMK1,SCH,YCC1, YCC3, YCC6, YCC7,
YCC10, YCC11 and YCC16. There was a significant
relationship between SPHK1 protein expression and
IC50 for cisplatin (R = 0.532 p = 0.013, Fig. 4b).
High SPHK1 protein expression is associated with poor
survival in Gastroesophageal cancer patients treated with
chemotherapy
We examined the expression levels of SPHK1 protein by
IHC in 67 gastroesophageal cancer patients (Table 1).
We observed expression of SPHK1 protein in the cytosol
in 60 (89 %) patients. There was no significant difference
between the clinico-pathological characteristics of those
patients that did and did not receive neo-adjuvant
chemotherapy (Table 1). When SPHK1 staining was
present, it was invariably present in virtually all tumour
cells and we observed minimal variation in the propor-
tion of tumour cells staining positive. The intensity of
SPHK1 staining was variable between tumours, and was
scored by 2 independent observers as negative, weak,
moderate or strong (Fig. 5a). There was no association
(χ2 test, p > 0.05) between SPHK1 staining as negative or
weak versus moderate or strong and any of the clinco-
pathological variables listed in table 1, in either entire
cohort (n = 67) or the neo-adjuvant chemotherapy and sur-
gery group (n = 36), nor the surgery alone group (n = 31).
Higher expression of SPHK1 correlated with poor sur-
vival in patients treated with cisplatin based combin-
ation chemotherapy before surgery, but not those who
received surgery alone without prior cisplatin based
chemotherapy(surgery only patients median survival
841 days for SPHK1 moderate or strong versus 330
days for SPHk1 negative or weak, HR = 0.79, 95 % CI
0.65-1.4, p = 0.0325 and neo-adjuvant chemotherapy
followed by surgery patients median survival 273 days
Fig. 4 Relationship between SPHK1 protein expression and cisplatin resistance in gastroesophageal cancer cell lines. a SPHK1 protein
expression determined by semi-quantitative immunohistochemistry Q-score(see text) correlates with SPHK1 mRNA expression in drug
resistant gastroesophageal cell lines(mean for all drug resistant cell lines and parental wild type lines, 3 independent replicates per cell
line from three different passages measured by qRT-PCR (see also Additional file 1: Additional information 5). (R = 0.70, p = 0.022). b SPHK1
protein expression determined by semi-quantitative immunohistochemistry Q-score(see text) with IC50 for cisplatin in an independent panel
of gastric cancer cell lines. (R = 0.532, p = 0.013)
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for SPHK1 moderate or strong versus 954 days for
SPHk1 negative or weak, HR = 1.67, 95 % CI 1.02-2.76,
p = 0.036 Figure 5b). Only Tumour stage remained sig-
nificant in a multivariate analysis with the input vari-
ables SPHK1 (negative or weak versus moderate or
strong), surgical resection margins(positive versus nega-
tive), histology (squamous versus adenocarcinoma), site
(oesophagus versus gastric) neo-adjuvant chemotherapy
(yes versus no) and tumour stage (I or II versus III).
Safingol reverses cisplatin resistance in a gastric
adenocarcinoma cell line
We investigated the ability of safingol, an inhibitor of
SPHK1, to reverse cisplatin resistance in gastric
adenocarcinoma. The combination of safingol and cis-
platin has been evaluated in a Phase I trial in solid tu-
mours and is a safe well tolerated combination [38].
Safingol had cytotoxic activity as a single agent and also
increased the cisplatin sensitivity of the highly cisplatin
resistant cell line AGScis5, and also the gastric cancer
cell line N87. In both cases cisplatin and safingol acted
synergistically with the combination index suggesting
strong synergy (Figs. 6a and b).
Discussion
We approached the clinical need to identify predictive
biomarkers for cytotoxic chemotherapy and new thera-
peutic targets in gastroesophageal cancer by using a
Fig. 5 SPHK1 expression in gastroesophageal cancer patients. a SPHK1 Immunohistochemistry. Representative examples (x400) of strong, moderate
and weak tumour SPHK1 staining and proportions of tumours in each category. b SPHK1 immunohistochemistry and overall survival of
oesophago-gastric cancer patients treated with either surgery alone or with neoadjuvant chemotherapy prior to surgical resection, grouped
negative or weak SPHK1 staining(blue line) versus moderate or strong SPHK1 staining (red line) (Kaplan- Meier survival curve, log rank test)
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hypothesis generating approach with global gene expres-
sion profiling of a panel of cell lines selected for resist-
ance to clinically used cytotoxics. In order to enable
rapid clinical translation, we prioritised further investiga-
tion of identified lead candidates for which agents
already exist, as these would provide new strategies for
combinations of targeted and cytotoxic therapies to
overcome resistance and increase clinical effectiveness.
Sphingosine metabolism was identified as a lead can-
didate target following gene expression profiling and
biological pathway mapping. In drug resistant gastro-
esophageal cancer cell lines we observed increased
levels of sphingosine metabolite, S1P and increased cis-
platin sensitivity in response to pharmacological inhib-
ition of SPHK1, a kinase required for metabolism of
sphingosine to S1P, as well as correlation between
SPHK1 protein expression and cisplatin sensitivity in
an independent gastric cancer cell line panel. Further-
more, SPHK1 protein expression was associated with
worse survival in a cohort of patients with gastroesoph-
ageal cancer who received cytotoxic neo-adjuvant
chemotherapy. Our data demonstrate an inverse rela-
tionship between the expression of SPHK1 (increased)
and SGPL1 (decreased) in resistant cell lines and we
propose this leads to increased cellular S1P and cyto-
toxic drug resistance.
S1P is a phospholipid with many functions, formed
intra-cellularly through the phosphorylation of sphingo-
sine by sphingosine kinases (2 isoforms SPHK1 and
SPHK2) [39]. S1P is actively transported out of the
cytosol to act via membrane S1P receptors, although re-
ceptor independent effects, including intracellular tar-
gets are also recognised [39]. Alternatively, irreversible
cleavage of S1P by SGPL1 can occur in the cytosol. A
role for SPHK1 and S1P in drug resistance in gastro-
esophageal cancer is consistent with many previous in-
vestigations, which have suggested a pathogenic role in
several cancer types including gastric cancer [21], where
SPHK1 overexpression is observed in tumour cells and
associated with increased stage and poor survival [20].
In addition, investigations in cancer and non-cancer cells
demonstrate that increased SPHK1 is associated with in-
creased production of S1P in cells and S1P promotes cell
proliferation, angiogenesis and inhibits cell death all of
which could promote cell survival following cytotoxic drug
insult and hence induce resistance [22–29, 37, 40, 41]. In
addition SPHK1 activity and levels of S1P have been dem-
onstrated to be involved in resistance to cytotoxic and tar-
geted agents in a variety of cancer types, although
not oesophageal or gastric adenocarcinoma drug resistance
[30, 31, 34–36, 40, 42]. Here we provide the first evidence
for the importance of sphingosine metabolism, and in par-
ticular SPHK1 and S1P, in resistance to cytotoxics in gas-
troesophageal cancer.
Accordingly S1P could lead to cytotoxic drug resist-
ance in gastroesophegal cancer acting in an autocrine or
paracrine manner via cell surface S1P receptors follow-
ing transportation out of the cytosol. Alternatively S1P
may mediate cytotoxic drug resistance acting intracellu-
larly by counteracting apoptosis mediated by its pro-
Fig. 6 Synergistic effects of cisplatin and safingol in gastroesophageal cancer cell lines. a AGSCIS5 cisplatin resistant gastric cancer cell line and
b N87 gastric cancer cell line. Cisplatin: Safingol ratio is constant in the combination experiments, and each data point has 6 replicates. Mean
growth from three independent experiments shown, relative cell survival ((MTT OD value for cells treated as indicated /MTT OD value for
untreated control)*100, ±SEM). Tables show combination index for cisplatin and safingol at different ICs for each cell line and show synergy
between the treatments across different doses
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apoptotic precursor ceramide or interaction with known
intracellular targets involved in cancer pathogenesis and
cytotoxic drug resistance such as Histone deacetylase 1
(HDAC1) and Histone deacetylase 2 (HDAC 2) to which
S1P directly binds and inhibits, and TNF Receptor-
Associated Factor 2 (TRAF 2), or Protein Kinase C
(PKC) [39]. Further investigation is required to determine
which of these potentially pleomorphic mechanisms is im-
portant for cytotoxic drug resistance in gastroesophageal
cancer, and the key mechanisms may be different for dif-
ferent drugs. Nevertheless our data demonstrates that S1P
production controlled by SPHK1 and SGPL1 are key de-
terminants of cytotoxic drug resistance and that decreas-
ing S1P production in cancer cells could lead to increased
cytotoxic sensitivity.
Rex et al. demonstrated no effect on the viability of
cancer cell lines (cultured with and without serum star-
vation), nor on the growth of xenografts, with the use of
highly specific SPHK1 and SPHK2 inhibitors [43]. How-
ever, the effect of SPHK1/2 inhibition under conditions
of exposure to cytotoxic drugs was not investigated. Ac-
cordingly, it is not possible to rule out the importance of
S1P and SPHK1 on tumour cell viability in specific cir-
cumstances not tested in their experiments- which
would include exposure to cytotoxics. In addition it is
possible that SPHK1 may have different effects in differ-
ent types of cancer, and while Rex et al., provide data on
a variety of cancer types, they have not provided data on
gastroesophageal cancer cell lines. Our experiments with
gastric adenocarcinoma cell lines suggest that safingol, a
SPHK1 inhibitor, has cytotoxic effects as a single agent
as well as acting synergistically with cisplatin.
Our finding of an inverse relationship between SPHK1
and SGPL1 expression in gastroesophageal cancer asso-
ciated with increased levels of S1P and cytotoxic drug
resistance is consistent with a recent report in prostate
cancer, where a similar inverse relationship between ex-
pression of SPHK1 and SGPL1 was noted leading to in-
creased production of S1P and an association with
resistance to docetaxel [37]. In addition, increased S1P
in glioblastoma multiforme tissues is associated with in-
creased SPHK1 and decreased expression of S1P phos-
phatase (SGPP2) [22]. Together with our data, these
observations suggest that increased SPHK1 and de-
creased SGPL1 or SGPP2 may be a relatively common
pathogenic mechanism that could also be involved with
therapy resistance in several cancer types.
Our data suggest that increased SPHK1 expression in
gastroesophageal cancers has predictive impact indicat-
ing chemotherapy resistance in gastroesophageal cancer
patients, consistent with our cell line findings, but not
therapy independent prognostic value. A previous study
by Li et al., demonstrated that high SPHK1 expression in
resected gastric cancers was associated with worse
survival [20]. Li et al., noted that the relationship be-
tween increased SPHK1 and survival was only significant
for patients with higher stage (III and IV) disease who
were often given adjuvant chemotherapy (chemotherapy
details not provided) after surgery and there was no sig-
nificant correlation between SPHK1 and survival for
early stage (I and II) disease patients who were not given
adjuvant chemotherapy after surgery. Given our findings
reporting an effect of SPHK1 on resistance to chemo-
therapy, this interaction between SPHK1 and chemo-
therapy may explain the contrasting findings by Li and
colleagues in early versus late stage disease. Pan et al.,
reported worse survival in esophageal squamous cell car-
cinoma patients treated with surgery alone (no neo-
adjuvant chemotherapy) who had high SPHK1 protein
expression [19]. Therefore, the impact of SPHK1 may
vary according to histological sub-type of gastroesopha-
geal cancer. Our investigation included 1 squamous cell
carcinoma oesophagus cell line (OE21), but only a mi-
nority (18 %) of patients in our clinical cohort had
squamous cell carcinomas. There was no observed asso-
ciation between SPHK1 IHC and histology and multi-
variate analysis did not suggest and differential effect of
SPHK1 in squamous versus adenocarcinoma (although
numbers were small in this analysis). Further prospective
studies are required to determine the interaction be-
tween SPHK1 (SGPL1 and/or S1P) and histological sub-
type and their therapy independent prognostic versus
predictive impact.
Here we have investigated the relationship between re-
sistance and benefit from neo-adjuvant chemotherapy in
gastroesophageal cancer patients. It would be valuable to
investigate the relationship between SPHK1 expression
and response to palliative chemotherapy to determine if
there is any differential impact according to the stage of
the disease. This would be useful in planning future clin-
ical trials of therapies targeting SPHK1. The small num-
bers of patients in our surgical cohort who would have
recurred and received palliative chemotherapy mean that
such an analysis in our cohort would not be informative.
In addition there may be a change in the SPHK1 expres-
sion from the primary tumour that was resected and the
recurrent disease at a later date when palliative chemo-
therapy might be administered. Investigation in a large
cohort of patients with advanced gastroeosphageal can-
cer that have received palliative chemotherapy would be
worthwhile. Further investigation of the relationship be-
tween the ratio of SPHK1 and SGPL1 protein expression
determined by immunohistochemistry or other methods,
and the response/benefit from both neo-adjuvant and
palliative chemotherapy in clinical cohorts of patients
would also be valuable.
There are a number of SPHK1 and S1P inhibitors in
clinical development as anti-cancer agents that confer
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increased sensitivity to cytotoxic drugs, targeted agents
or radiotherapy and/or have single agent activity in pre-
clinical cancer models [30, 31, 38, 44–49] (Table 2).
Therefore our findings in gastroesophageal cancer could
be readily translatable to the clinic. SPHK1 may be a
useful biomarker to identify patients who are likely to be
resistant to cytotoxic chemotherapy and who would
benefit from the addition of a SPHK1 or S1P inhibitor to
a cytotoxic chemotherapy regimen. Alternatively, SPHK1
and S1P inhibitors may be useful as part of second line
therapies in patients who have clinical resistance to cyto-
toxic chemotherapy, a situation where current therapies
have limited efficacy. We investigated this in vitro by
examining the effect of safingol on cisplatin resistance in
gastric cancer. We chose safingol (L-theo dihydrospingo-
sine) rather than a more specific SPHK1 inhibitor or
SPHK1 knock down by siRNA mediated knock down of
SPHK1, since it is the most developed SPHK1/S1P in-
hibitor as an anti-cancer agent and in particular safingol
has demonstrated safety in combination with cisplatin in
a phase I clinical trial and lead to decreased serum S1P
in treated patients [38]. Accordingly using safingol
would provide useful data to facilitate more rapid trans-
lation to a clinical therapy and similar to the phase I
trial, we investigated the combination of cisplatin safin-
gol in gastrooesophegal cell lines. Safingol is a potent
competitive inhibitor of SPHK1 with a Ki <0.4 μM, it is
a substrate for but not inhibitor of SPHK2, and it is also
known to inhibit PKC but the Ki is considerably higher
at 33–40 μM [50–53]. In addition safingol treatment of
colon cancer cells leads to decreased S1P and increased
sphingosine [46]. In our evaluation of safingol in the cis-
platin resistant cell line AGSCIS4 and the gastric cancer
cell line N87 we used safingol at concentrations ranging
from 0.375–12 μM, which is well within the readily
achievable serum plasma concentrations of safingol in
cancer patients and at which significant decreases in
serum S1P are reported [38]. As well as synergy with cis-
platin our experiments demonstrated cytotoxic activity
of safingol, which together with the safety data from the
clinical phase I trial with concomitant cisplatin adminis-
tration suggest that this would be a feasible and appro-
priate combination to investigate in early phase trials in
gastroesophageal cancer patients. Further pre-clincial ex-
periments with specific SPHK1 inhibitors and siRNA
mediated knockdown of SHK1 would allow additional
exploration of the potential of SPHK1 as a target and
the usefulness of combining with other cytotoxic and
targeted drugs.
Conclusion
In conclusion, we have demonstrated for the first time
in gastroesophageal cancer that increased SPHK1 occurs
in combination with decreased SGPL1 and increased
S1P, and cytotoxic drug resistance, and that a SPHK1 in-
hibitor safingol can reverse cisplatin resistance. Given
the demonstrated clinical safety and tolerability of safin-
gol in combination with cisplatin, as well as the availabil-
ity of several other SPHK1 and S1P inhibitors in stage
clinical development, we suggest that combining such
agents with cytotoxic chemotherapy or investigating
their activity in patients who have developed secondary
resistance to chemotherapy is a promising clinical strat-
egy and that a high tumour SPHK1:SGPL1 ratio could
provide a predictive biomarker to select patients for this
therapeutic approach.
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